PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - Crandall, David T
ED  - Glick, Ira D
ED  - Kane, John M
ED  - Janicak, Philip G
ED  - Meyer, Jonathan M
TI  - Aripiprazole for the Treatment of Schizophrenia—Selected Posters
DP  - 2008 Nov 01
TA  - MD Conference Express
PG  - 15--16
VI  - 8
IP  - 3
4099  - http://mdc.sagepub.com/content/8/3/15.2.short
4100  - http://mdc.sagepub.com/content/8/3/15.2.full
AB  - The goals for the management of schizophrenia and schizoaffective disorders are to decrease severity and frequency of psychosis and associated mood symptoms while reducing the inherent risks of antipsychotic medications. Aripiprazole demonstrates agonist activity toward dopamine D2 and 5-HT1a receptors and antagonizes 5-HT2a receptors, sites that are associated with psychosis and mood disorders.